BOLT vs. LAZR

Last updated Apr 1, 2026

Compare and contrast key facts about Bolt Biotherapeutics, Inc. (BOLT) and Luminar Technologies, Inc. (LAZR).

Performance

BOLT vs. LAZR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bolt Biotherapeutics, Inc. (BOLT) and Luminar Technologies, Inc. (LAZR). The values are adjusted to include any dividend payments, if applicable.

BOLT vs. LAZR - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
BOLT Bolt Biotherapeutics, Inc.	-26.12%	-48.91%	-52.22%	-13.85%	-73.47%	-84.76%
LAZR Luminar Technologies, Inc.	0.00%	-96.50%	-89.36%	-31.92%	-70.73%	-49.30%

Fundamentals

EPS BOLT : -$17.54 LAZR : -$3.95
PS Ratio BOLT : 1.00 LAZR : 0.15
Total Revenue (TTM) BOLT : $7.70M LAZR : $75.75M
Gross Profit (TTM) BOLT : $7.93M LAZR : -$16.13M
EBITDA (TTM) BOLT : -$33.77M LAZR : -$161.26M

Returns By Period

BOLT

• 1D: -4.94%
• 1M: -10.62%
• YTD: -26.12%
• 6M: -24.06%
• 1Y: -49.50%
• 3Y*: -47.43%
• 5Y*: -63.57%
• 10Y*: —

LAZR

• 1D: 0.00%
• 1M: 0.00%
• YTD: 0.00%
• 6M: -90.14%
• 1Y: -96.50%
• 3Y*: -87.54%
• 5Y*: -78.01%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BOLT vs. LAZR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BOLT

BOLT Risk / Return Rank: 9
BOLT Sharpe Ratio Rank: 13
BOLT Sortino Ratio Rank: 13
BOLT Omega Ratio Rank: 16
BOLT Calmar Ratio Rank: 0
BOLT Martin Ratio Rank: 5

LAZR

LAZR Risk / Return Rank: 11
LAZR Sharpe Ratio Rank: 23
LAZR Sortino Ratio Rank: 9
LAZR Omega Ratio Rank: 7
LAZR Calmar Ratio Rank: 3
LAZR Martin Ratio Rank: 14

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BOLT vs. LAZR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bolt Biotherapeutics, Inc. (BOLT) and Luminar Technologies, Inc. (LAZR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BOLT	LAZR	Difference
Sharpe ratio Return per unit of total volatility	-0.68	-0.41	-0.27
Sortino ratio Return per unit of downside risk	-0.87	-1.19	+0.32
Omega ratio Gain probability vs. loss probability	0.91	0.81	+0.09
Calmar ratio Return relative to maximum drawdown	-1.02	-0.99	-0.04
Martin ratio Return relative to average drawdown	-1.70	-1.36	-0.34
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BOLT vs. LAZR - Sharpe Ratio Comparison

The current BOLT Sharpe Ratio is -0.68, which is lower than the LAZR Sharpe Ratio of -0.41. The chart below compares the historical Sharpe Ratios of BOLT and LAZR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BOLT	LAZR	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.68	-0.41	-0.27
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.86	-0.59	-0.27
Sharpe Ratio (All Time) Calculated using the full available price history	-0.84	-0.53	-0.31

Correlation

The correlation between BOLT and LAZR is 0.20, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BOLT vs. LAZR - Dividend Comparison

Neither BOLT nor LAZR has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

BOLT vs. LAZR - Drawdown Comparison

The maximum BOLT drawdown since its inception was -99.51%, roughly equal to the maximum LAZR drawdown of -99.97%. Use the drawdown chart below to compare losses from any high point for BOLT and LAZR.

Drawdown Indicators

	BOLT	LAZR	Difference
Max Drawdown Largest peak-to-trough decline	-99.51%	-99.97%	+0.46%
Max Drawdown (1Y) Largest decline over 1 year	-51.25%	-96.39%	+45.14%
Max Drawdown (5Y) Largest decline over 5 years	-99.38%	-99.95%	+0.57%
Current Drawdown Current decline from peak	-99.49%	-99.97%	+0.48%
Average Drawdown Average peak-to-trough decline	-89.73%	-61.84%	-27.89%
Ulcer Index Depth and duration of drawdowns from previous peaks	30.86%	70.94%	-40.08%

Volatility

BOLT vs. LAZR - Volatility Comparison

Bolt Biotherapeutics, Inc. (BOLT) has a higher volatility of 22.94% compared to Luminar Technologies, Inc. (LAZR) at 0.00%. This indicates that BOLT's price experiences larger fluctuations and is considered to be riskier than LAZR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BOLT	LAZR	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.94%	0.00%	+22.94%
Volatility (6M) Calculated over the trailing 6-month period	53.19%	196.29%	-143.10%
Volatility (1Y) Calculated over the trailing 1-year period	72.74%	238.57%	-165.83%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	74.05%	133.12%	-59.07%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.98%	117.29%	-42.31%

Financials